Siemens Healthineers stock weighs strong Q4 against softer 2027 outlook

Published on 11/10/2026 at 11:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Siemens Healthineers stock enters investor meetings after a strong fourth quarter. Management expects slower earnings growth in fiscal 2027.

Strong Quarter Meets Cautious Outlook

Fiscal 2026 comparable revenue growth reached 4.0 percent, with adjusted basic earnings per share of 2.42 euros.
Imaging led the fourth quarter, while Diagnostics posted a comparable revenue decline.
Management expects fiscal 2027 comparable revenue growth of 4.0 to 5.0 percent and adjusted basic earnings per share of 2.20 to 2.40 euros.

Siemens Healthineers, DE000SHL1006, Illustration mit AI erstellt.

Siemens Healthineers stock traded at 43.30 euros on Lang & Schwarz at 11:44 CET on Tuesday, November 10, 2026. The medical technology group is meeting investors after reporting a strong fiscal 2026 fourth quarter, but its forecast points to a more demanding earnings year ahead.

Fourth-quarter growth led by Imaging

In its November 5 press release, Siemens Healthineers reported comparable fourth-quarter revenue growth of 5.9 percent for the period ended September 30, 2026. Imaging grew 10.0 percent on a comparable basis, while Precision Therapy advanced 4.8 percent.

Diagnostics was the weak spot, with comparable revenue declining 4.2 percent. The division reported an adjusted EBIT margin of 5.4 percent, compared with 21.9 percent for Imaging and 13.8 percent for Precision Therapy. Group adjusted basic earnings per share came to 0.69 euros, and free cash flow reached 703 million euros.

The company also reported a fourth-quarter equipment book-to-bill ratio of 1.15, indicating that equipment orders exceeded shipments during the period. For the full fiscal year, the ratio was 1.14.

2027 forecast puts earnings under pressure

Management expects comparable revenue growth of 4.0 to 5.0 percent in fiscal 2027. Adjusted basic earnings per share are forecast at 2.20 to 2.40 euros, below the 2.42 euros achieved in fiscal 2026 even at the top of the range.

Chief Executive Bernd Montag said the company was entering a new phase with a different shareholder structure and greater corporate clarity. The group is also sharpening its portfolio, positioning Diagnostics for the future and starting the carve-out process. The company plans to evolve its brand and use the name Healthineers.

The fiscal 2026 figures provide a strong operating base, but the outlook signals that investors will focus on the conversion of revenue growth into earnings. Diagnostics remains a central execution issue, while the planned portfolio and structural changes add further milestones to the investment case.

Investor meetings keep outlook in focus

The company's investor relations page lists meetings in Frankfurt, Paris and London on Tuesday, November 10, following the fiscal 2026 results. Management's 2027 growth and earnings assumptions are likely to remain central topics for investors.